Nuvalent (NASDAQ:NUVL) Given “Buy” Rating at HC Wainwright

Nuvalent (NASDAQ:NUVL)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Tuesday, Marketbeat Ratings reports. They currently have a $130.00 price objective on the stock, up from their prior price objective of $110.00. HC Wainwright’s price target indicates a potential upside of 64.37% from the company’s previous close. HC Wainwright also issued estimates for Nuvalent’s Q4 2026 earnings at ($0.52) EPS, FY2026 earnings at ($3.19) EPS, FY2027 earnings at ($0.12) EPS, FY2028 earnings at $2.96 EPS and FY2029 earnings at $7.50 EPS.

Separately, UBS Group raised shares of Nuvalent from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $119.60.

Nuvalent Stock Up 2.9%

Shares of NUVL stock opened at $79.09 on Tuesday. Nuvalent has a 12-month low of $55.54 and a 12-month high of $113.51. The firm has a market capitalization of $5.68 billion, a price-to-earnings ratio of -18.02 and a beta of 1.34. The firm has a fifty day moving average of $74.42 and a 200-day moving average of $76.53.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.14) by ($0.04). During the same quarter in the prior year, the business earned ($0.69) EPS. Research analysts expect that Nuvalent will post -3.86 earnings per share for the current year.

Insiders Place Their Bets

In other Nuvalent news, CEO James Richard Porter sold 27,000 shares of the business’s stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $68.94, for a total transaction of $1,861,380.00. Following the sale, the chief executive officer now directly owns 249,062 shares of the company’s stock, valued at $17,170,334.28. The trade was a 9.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 10.20% of the company’s stock.

Institutional Investors Weigh In On Nuvalent

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Crowley Wealth Management Inc. bought a new stake in Nuvalent during the 4th quarter worth about $27,000. CWM LLC raised its holdings in shares of Nuvalent by 588.5% in the 1st quarter. CWM LLC now owns 420 shares of the company’s stock valued at $30,000 after purchasing an additional 359 shares during the period. ANTIPODES PARTNERS Ltd bought a new stake in shares of Nuvalent in the 1st quarter valued at about $38,000. Quarry LP bought a new stake in shares of Nuvalent in the 4th quarter valued at about $39,000. Finally, Covestor Ltd increased its position in Nuvalent by 705.7% during the first quarter. Covestor Ltd now owns 983 shares of the company’s stock worth $70,000 after buying an additional 861 shares during the last quarter. 97.26% of the stock is owned by institutional investors.

About Nuvalent

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.